121 related articles for article (PubMed ID: 22075086)
1. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates.
Morera Y; Bequet-Romero M; Ayala M; Pérez PP; Castro J; Sánchez J; Alba JS; Ancízar J; Cosme K; Gavilondo JV
Vaccine; 2012 Jan; 30(2):368-77. PubMed ID: 22075086
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates.
Morera Y; Bequet-Romero M; Ayala M; Velazco JC; Pérez PP; Alba JS; Ancizar J; Rodríguez M; Cosme K; Gavilondo JV
Vaccine; 2010 Apr; 28(19):3453-61. PubMed ID: 20197134
[TBL] [Abstract][Full Text] [Related]
3. Experimental studies of a vaccine formulation of recombinant human VEGF antigen with aluminum phosphate.
Pérez Sánchez L; Morera Díaz Y; Bequet-Romero M; Ramses Hernández G; Rodríguez Y; Castro Velazco J; Puente Pérez P; Ayala Avila M; Gavilondo JV
Hum Vaccin Immunother; 2015; 11(8):2030-7. PubMed ID: 25891359
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Selman-Housein Bernal KH; de la Torre Santos A; Santiesteban Álvarez ER; Martín Bauta Y; Bermúdez Badell CH; de la Torre Pupo J; Gavilondo JV; ; Ayala Avila M
BMC Immunol; 2017 Jul; 18(1):39. PubMed ID: 28747172
[TBL] [Abstract][Full Text] [Related]
5. CIGB-247: a VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors.
Bequet-Romero M; Morera Y; Ayala-Ávila M; Ancizar J; Soria Y; Blanco A; Suárez-Alba J; Gavilondo JV
Vaccine; 2012 Feb; 30(10):1790-9. PubMed ID: 22240345
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
7. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Morera Y; Sánchez J; Bequet-Romero M; Selman-Housein KH; de la Torre A; Hernández-Bernal F; Martín Y; Garabito A; Piñero J; Bermúdez C; de la Torre J; Ayala M; Gavilondo JV
Vaccine; 2017 Jun; 35(28):3582-3590. PubMed ID: 28536029
[TBL] [Abstract][Full Text] [Related]
8. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV; Hernández-Bernal F; Ayala-Ávila M; de la Torre AV; de la Torre J; Morera-Díaz Y; Bequet-Romero M; Sánchez J; Valenzuela CM; Martín Y; Selman-Housein KH; Garabito A; Lazo OC;
Vaccine; 2014 Apr; 32(19):2241-50. PubMed ID: 24530151
[TBL] [Abstract][Full Text] [Related]
9. Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Sánchez Ramírez J; Morera Díaz Y; Bequet-Romero M; Hernández-Bernal F; Martín Bauta Y; Selman-Housein Bernal KH; de la Torre Santos AV; Pérez de la Iglesia M; Trimiño Lorenzo L; ; Ayala Avila M
BMC Immunol; 2020 Mar; 21(1):12. PubMed ID: 32171254
[TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
11. Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
Gabri MR; Mazorra Z; Ripoll GV; Mesa C; Fernandez LE; Gomez DE; Alonso DF
Clin Cancer Res; 2006 Dec; 12(23):7092-8. PubMed ID: 17145833
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model.
Morera Y; González R; Lamdan H; Pérez L; González Y; Agüero J; Castro J; Romero JC; Etchegoyen AY; Ayala M; Gavilondo JV
Exp Eye Res; 2014 May; 122():102-9. PubMed ID: 24675387
[TBL] [Abstract][Full Text] [Related]
13. [Study on the specific immunity induced by dendritic cell vaccine loading allogenic microvascular endothelial cell bEnd.3 antigen against U14 cervical cancer cell in mice].
Zhao J; Lu J; Liu YQ; Yang HY; Huang YT; Zhao JM; Li S; Zhai JM; Zhao MY; Zhang X; Dong ZM
Zhonghua Fu Chan Ke Za Zhi; 2011 Jan; 46(1):52-7. PubMed ID: 21429436
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
15. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside.
Morera-Díaz Y; Gavilondo JV; Bequet-Romero M; Sánchez Ramírez J; Hernández-Bernal F; Selman-Housein KH; Perez L; Ayala-Ávila M
Semin Oncol; 2018 Jan; 45(1-2):68-74. PubMed ID: 30318086
[TBL] [Abstract][Full Text] [Related]
16. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
[TBL] [Abstract][Full Text] [Related]
17. Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
Sánchez Ramírez J; Bequet-Romero M; Morera Díaz Y; Hernández-Bernal F; Ayala Avila M
BMC Res Notes; 2019 Jun; 12(1):323. PubMed ID: 31182141
[TBL] [Abstract][Full Text] [Related]
18. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.
Castellanos M; Cinza Z; Dorta Z; Veliz G; Vega H; Lorenzo I; Ojeda S; Dueñas-Carrera S; Alvarez-Lajonchere L; Martínez G; Ferrer E; Limonta M; Linares M; Ruiz O; Acevedo B; Torres D; Márquez G; Herrera L; Arús E
J Gene Med; 2010 Jan; 12(1):107-16. PubMed ID: 19866482
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
